ReviewCureus2026
Daraxonrasib: A Breakthrough in Pancreatic Ductal Adenocarcinoma.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic cancer is one of the leading causes of cancer-related mortality. Diagnosis at an advanced stage, aggressive tumor biology, and chemoresistance all contribute to the overall dismal prognosis. Somatic, non-hereditary activating mutations involving the proto-oncogene Kirsten rat sarcoma viral oncogene (KRAS) are encountered in the vast majority of patients. KRAS mutations are involved in tumor initiation as well as the progression of pancreatic cancer and are key determinants of prognosis. Beyond pancreatic ductal adenocarcinoma (PDAC), KRAS mutations have been reported in multiple human solid-organ neoplasms. Over the past few decades, targeted molecular therapy has evolved into an indispensable part of oncology. Molecules targeting rat sarcoma viral oncogene (RAS) mutations have gained considerable interest in molecular oncology owing to their pivotal role in common cancers such as non-small cell lung, colon, and pancreatic cancer. One of the recent breakthroughs in PDAC treatment is the discovery of the multi-selective RAS inhibitor specific to its ON conformation: the first of its class, the RAS(ON) inhibitor daraxonrasib. Preclinical and early clinical data confirmed its utility in PDAC, leading to United States Food and Drug Administration permission to expand access treatment protocols for patients with previously treated metastatic PDAC in May 2026. This narrative review summarizes the published literature on the safety and efficacy of daraxonrasib in PDAC, based on a comprehensive PubMed literature search. As of June 2026, the utility of daraxonrasib is limited to metastatic PDAC as a second-line agent in patients who failed or were intolerant of first-line chemotherapy. An ongoing trial is evaluating the efficacy of daraxonrasib as a first-line targeted therapy in metastatic PDAC. Further, large-scale, blinded, multicenter randomized trials are required to confirm the efficacy and safety of daraxonrasib in PDAC and other solid-organ neoplasms. The orally administered daraxonrasib could be a potential game changer in the treatment of PDAC, which is otherwise considered one of the least chemotherapy-amenable human cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.